Brief: Prescient Therapeutics Extends Covid-19 Testing Program With Doherty Institute
09/12/2020 24:41
Dec 9 (Reuters) - Prescient Therapeutics Ltd PTX.AX :
* PTX EXTENDS COVID-19 TESTING PROGRAM WITH DOHERTY
INSTITUTE-PTX.AX
* TO EXTEND TESTING PROGRAM FOR SARS-COV-2 ANTIVIRAL DRUGS
OF
PRESCIENT'S ASSETS, BEING CONDUCTED BY DOHERTY INSTITUTE
* PURPOSE OF EVALUATION TO DETERMINE ANTIVIRAL ACTIVITY OF
ASSETS
IN SARS-COV-2 INFECTED VERO CELLS
* INITIAL FINDINGS FROM FIRST TESTS WERE INCONCLUSIVE
Source text for Eikon: ID:nASX6PpqKv
Further company coverage: PTX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prescient Therapeutics
See all newsAustralia's Prescient Therapeutics falls on discounted share placement
Brief: Prescient Therapeutics Raises A$4.8 Million Via SPP, A$1.2 Million In Placement
Brief: Prescient Therapeutics Says Trading Halt Requested
Australia's Prescient Therapeutics hits near 2-month low on discounted raise
Brief: Prescient Therapeutics Secures EU Authorisation To Commence PTX-100 Clinical Trial